Nichols & Pratt Advisers LLP MA Has $1.37 Million Stake in Amgen Inc. (NASDAQ:AMGN)

Nichols & Pratt Advisers LLP MA grew its holdings in Amgen Inc. (NASDAQ:AMGNFree Report) by 12.3% during the 3rd quarter, according to the company in its most recent filing with the SEC. The fund owned 5,094 shares of the medical research company’s stock after purchasing an additional 557 shares during the period. Nichols & Pratt Advisers LLP MA’s holdings in Amgen were worth $1,369,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently modified their holdings of the business. OFI Invest Asset Management bought a new stake in Amgen during the 3rd quarter worth $26,000. Briaud Financial Planning Inc bought a new stake in Amgen during the 3rd quarter worth $26,000. IAG Wealth Partners LLC grew its position in Amgen by 520.0% during the 2nd quarter. IAG Wealth Partners LLC now owns 124 shares of the medical research company’s stock worth $28,000 after acquiring an additional 104 shares during the last quarter. VisionPoint Advisory Group LLC bought a new stake in Amgen during the 2nd quarter worth $28,000. Finally, Strategic Investment Solutions Inc. IL bought a new stake in Amgen during the 1st quarter worth $28,000. Institutional investors own 74.44% of the company’s stock.

Amgen Trading Down 0.1 %

Shares of NASDAQ:AMGN opened at $290.70 on Monday. The stock has a market capitalization of $155.58 billion, a price-to-earnings ratio of 23.31, a PEG ratio of 2.74 and a beta of 0.62. The company has a debt-to-equity ratio of 10.14, a quick ratio of 1.13 and a current ratio of 1.65. The stock’s 50-day simple moving average is $295.30 and its two-hundred day simple moving average is $274.74. Amgen Inc. has a 52-week low of $211.71 and a 52-week high of $329.72.

Amgen (NASDAQ:AMGNGet Free Report) last posted its quarterly earnings data on Tuesday, February 6th. The medical research company reported $4.71 EPS for the quarter, topping the consensus estimate of $4.66 by $0.05. Amgen had a return on equity of 154.27% and a net margin of 23.83%. The firm had revenue of $8.20 billion for the quarter, compared to the consensus estimate of $8.13 billion. During the same quarter last year, the company earned $4.09 earnings per share. The business’s revenue for the quarter was up 19.8% compared to the same quarter last year. Analysts expect that Amgen Inc. will post 19.54 EPS for the current year.

Amgen Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Thursday, March 7th. Investors of record on Friday, February 16th will be paid a dividend of $2.25 per share. This represents a $9.00 annualized dividend and a yield of 3.10%. The ex-dividend date is Thursday, February 15th. This is an increase from Amgen’s previous quarterly dividend of $2.13. Amgen’s dividend payout ratio (DPR) is 68.21%.

Insider Activity at Amgen

In related news, SVP Nancy A. Grygiel sold 2,096 shares of Amgen stock in a transaction that occurred on Monday, December 4th. The stock was sold at an average price of $273.03, for a total transaction of $572,270.88. Following the sale, the senior vice president now owns 10,874 shares of the company’s stock, valued at approximately $2,968,928.22. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.57% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

A number of research firms have weighed in on AMGN. Morgan Stanley decreased their target price on shares of Amgen from $281.00 to $278.00 and set an “equal weight” rating for the company in a research report on Wednesday, February 7th. JPMorgan Chase & Co. reiterated a “neutral” rating and issued a $270.00 price objective on shares of Amgen in a research note on Friday, October 20th. BMO Capital Markets raised shares of Amgen from a “market perform” rating to an “outperform” rating and lifted their price target for the company from $286.00 to $326.00 in a research report on Tuesday, December 19th. downgraded shares of Amgen from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, February 7th. Finally, Daiwa Capital Markets raised shares of Amgen from a “neutral” rating to a “buy” rating and lifted their price objective for the stock from $264.00 to $320.00 in a report on Thursday, December 21st. One equities research analyst has rated the stock with a sell rating, eight have issued a hold rating and eleven have given a buy rating to the company. Based on data from, Amgen has an average rating of “Moderate Buy” and an average target price of $295.30.

Get Our Latest Report on Amgen

Amgen Company Profile

(Free Report)

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization.

Featured Articles

Want to see what other hedge funds are holding AMGN? Visit to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGNFree Report).

Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with's FREE daily email newsletter.